Welcome to our dedicated page for SUPERNUS PHARMACEUTICALS SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SUPERNUS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SUPERNUS PHARMACEUTICALS's regulatory disclosures and financial reporting.
Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,904 common shares by an insider through Morgan Stanley Smith Barney, with an aggregate market value of $91,468.16 and an approximate sale date of 10/02/2025 on NASDAQ. The filing states the shares were acquired the same day by exercise of stock options and paid in cash.
The notice also lists multiple prior 10b5-1 sales by the same account during Aug–Oct 2025, including transactions such as 40,173 shares for $1,931,063.89 on 10/01/2025 and several large sales in August and September 2025. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Jack A. Khattar, President and CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on 10/01/2025 showing the acquisition and sale of company common stock. He acquired 53,785 shares pursuant to an employee stock option with an exercise price of $25.30 and also sold 40,173 shares at a weighted average price of $48.07. The acquisition was made under a 10b5-1 trading plan adopted November 14, 2024, and the sale occurred in multiple transactions at prices ranging from $48.00 to $48.25.
After these transactions Mr. Khattar directly beneficially owns 1,160,870 shares and indirectly (through the KBT Trust) holds 1,005,600 shares, for a combined reported interest disclosed on the form. The exercised option vests in four equal installments beginning on 02/24/2018 and expires on 02/24/2027.
Insider notice to sell 40,173 common shares of Supernus Pharmaceuticals (SUPN) is reported under Form 144. The sale is scheduled for 10/01/2025 through Morgan Stanley Smith Barney and the aggregate market value of the proposed sale is $1,919,867.67. The shares were acquired on 10/01/2025 by exercise of stock options and payment was made in cash on the same date. The filing shows 56,073,088 shares outstanding for the class referenced. The filing also lists multiple prior 10b5-1 sales by the same account over the past three months totaling 304,123 shares.
Jack A. Khattar, President, CEO and director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/30/2025. He exercised an employee stock option to acquire 11,510 shares at an exercise price of $25.30 per share under a plan adopted 02/24/2018, and sold 8,588 shares in multiple trades at a weighted average price of $48.25 (individual sale prices ranged $48.00–$48.44). After these transactions Mr. Khattar beneficially owned 1,147,258 shares directly and an additional 1,005,600 shares indirectly through the KBT Trust. The option activity leaves 137,302 option shares outstanding held directly.
Form 144 filing for SUPN reports a proposed sale of 8,588 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 09/30/2025 on NASDAQ with an aggregate market value of $408,788.80. The filing states these shares were acquired and will be paid for on 09/30/2025 by exercise of stock options from the issuer. The document also lists multiple recent Rule 10b5-1 sales by Jack A. Khattar totaling numerous transactions in August and September 2025, including sales on 09/29/2025, 09/23/2025, 09/22/2025, and earlier dates, each showing amounts and gross proceeds. The filing shows total shares outstanding of 56,073,088, providing context for the size of the proposed sale within the company's capitalization.
Jack A. Khattar, President & CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported option-related and open-market transactions on 09/29/2025. He acquired 13,688 shares by exercising employee stock options at an exercise price of $25.30 and, on the same date, sold 10,235 shares in transactions at a weighted average price of $48.02 (sales ranged from $48.00 to $48.14). After these transactions he beneficially owns 1,144,336 shares directly and 1,005,600 shares indirectly through the KBT Trust; he also holds 148,812 option shares underlying employee stock options. The exercise was recorded as part of an option vesting schedule; the sales were made pursuant to a 10b5-1 trading plan adopted November 14, 2024. The form was signed by an attorney-in-fact on 09/30/2025.
Form 144 notice for SUPN (Supernus Pharmaceuticals, Inc.) shows an insider sale filing for common stock scheduled with Morgan Stanley Smith Barney. The filer reports proposing to sell 10,235 shares on 09/29/2025 with an aggregate market value of $481,352.05. The shares were acquired the same day (09/29/2025) via exercise of stock options and payment was in cash. The filing lists total shares outstanding of 56,073,088, which places the proposed sale at a very small fraction of outstanding stock. The notice also discloses multiple Rule 10b5-1 sales by Jack A. Khattar during August–September 2025 totaling 285,300 shares for combined gross proceeds of approximately $12,588,665.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 plan representations.
Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals (SUPN), reported transactions on 09/25/2025 relating to Performance Share Units (PSUs). 1,875 shares of common stock were acquired on settlement of PSUs at $0 (transaction code M) and 840 shares were withheld to satisfy tax withholding at a price of $46.21 (transaction code F).
Following these transactions, Mr. Rubin beneficially owned 11,015 shares (direct ownership). The filing notes the PSUs were granted on February 22, 2024, with certain awards vesting upon achievement of individual performance objectives established June 24, 2024.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/23/2025. He acquired 47,940 shares by exercising employee stock options with an exercise price of $12.98 (options vested in installments beginning 03/01/2017; expiration 03/01/2026). On the same date he sold 29,513 shares in multiple transactions at a weighted average price of $47.23. The acquisition was made pursuant to a 10b5-1 trading plan adopted 11/14/2024. Following these transactions his direct beneficial ownership is reported as 1,140,883 shares, and he also holds 1,005,600 shares indirectly through the KBT Trust. The form was signed by an attorney-in-fact on 09/24/2025.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/22/2025. He exercised 27,060 employee stock options with an exercise price of $12.98 (resulting from options granted earlier) and acquired 27,060 shares. On the same date he sold 16,587 shares at a weighted-average price of $47.02. Following these transactions the filing shows 1,122,456 shares beneficially owned directly and 1,005,600 shares indirectly through the KBT Trust. The exercise and acquisition were reported as made pursuant to a 10b5-1 trading plan adopted November 14, 2024. The Form 4 was signed by an attorney-in-fact on 09/23/2025.